logo
Plus   Neg
Share
Email

Stock Alert: Vaxart Jumps 11%

Shares of Vaxart Inc. (VXRT) are currently gaining over 11% on Tuesday morning. The company reported positive data from an early stage study of its oral Covid-19 vaccine candidate suggesting broad cross-reactivity against other coronaviruses. The company also announced that it has enrolled the first subject in a Phase 1b boosting regimen trial of its norovirus vaccine candidate.

VXRT is currently trading at $8.92, up $0.90 or 11.21%, on the Nasdaq.

Data from the Phase 1 study of Vaxart's oral Covid-19 vaccine candidate, VXA-CoV2-1 showed substantial T-cell responses, higher than the Pfizer and Moderna vaccines, the company said.

"CD8+ T-cells produced by our vaccine can recognize and are capable of destroying cells infected with the virus, including in the mucosa. The strength of T-cell responses against both S and N proteins, which we targeted, leads us to believe that VXA-CoV2-1 offers a promising solution to variants," said Dr. Sean Tucker, chief scientific officer at Vaxart.

Meanwhile, the clinical-stage biotechnology company said it has enrolled the first subject in a Phase 1b boosting regimen trial of its norovirus vaccine candidate. The study is designed to evaluate the safety and immunogenicity of various dosing intervals for Vaxart's candidate, which is the only clinical stage norovirus oral tablet vaccine actively being developed.

For comments and feedback contact: editorial@rttnews.com

RELATED NEWS
Follow RTT